Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV003650752 | SCV001394043 | pathogenic | Familial adenomatous polyposis 1 | 2022-08-18 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 950286). This variant has not been reported in the literature in individuals affected with APC-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Leu1489*) in the APC gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 1355 amino acid(s) of the APC protein. This variant disrupts a region of the APC protein in which other variant(s) (p.Tyr2645Lysfs*14) have been determined to be pathogenic (PMID: 1316610, 8381579, 9824584, 27081525). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. This variant is expected to disrupt the EB1 and HDLG binding sites, which mediate interactions with the cytoskeleton (PMID: 15311282, 17293347). While functional studies have not been performed to directly test the effect on APC protein function, this suggests that disruption of the C-terminal portion of the protein is functionally important. For these reasons, this variant has been classified as Pathogenic. |
| Myriad Genetics, |
RCV003336346 | SCV004044859 | pathogenic | Familial adenomatous polyposis 1 | 2023-05-11 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. |